NCT02034747View on ClinicalTrials.gov

A Study to Assess the Efficacy and Safety of Advagraf® Switching From Cyclosporine Between the Group That Was Treated With a 50% Reduced Corticosteroid and the Group With Maintained Corticosteroid for Stable Kidney Transplant Recipients

PHASE4CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

November 21, 2013

Primary Completion Date

November 7, 2015

Study Completion Date

November 7, 2015

Conditions
Kidney Transplant
Interventions
DRUG

Advagraf

oral

DRUG

Corticosteroid

oral

Trial Locations (9)

Unknown

Busan

Chungcheongnam-do

Daegu

Gyeonggi-do

Incheon

Jeollabuk-do

Jeollanam-do

Seoul

Ulsan

All Listed Sponsors
lead

Astellas Pharma Korea, Inc.

INDUSTRY

NCT02034747 - A Study to Assess the Efficacy and Safety of Advagraf® Switching From Cyclosporine Between the Group That Was Treated With a 50% Reduced Corticosteroid and the Group With Maintained Corticosteroid for Stable Kidney Transplant Recipients | Biotech Hunter | Biotech Hunter